Alta Sciences

JUNE 9, 2023

Accelerating Global Drug Development Timelines With Ethnobridging rmaloney Mon, 06/12/2023 - 16:07 HTML Safe Strategy to Save Time and Money Avoid repeating Phase I studies for drugs intended for the Asian market. Download your copy today. In this complimentary webinar , Mel B.

Drug Development 40

Drug Development Clinical Trials Biosimilars Pharmacokinetics 40

Alta Sciences

JULY 20, 2023

A Proactive Drug Development Solution for Your Biologics nbartlett Thu, 07/20/2023 - 15:37 HTML The process of biologic drug development, from lead molecule identification to approval, can be long and complicated. Download now. Altasciences is here to help streamline the process. Fact Sheet: Biologics/Biosimilars.

Drug Development 40

Drug Development Biosimilars Drugs Therapies 40

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization. Substantial global capabilities.

Clinical Research 98

Clinical Research Pharmaceutical Companies Clinical Development Drug Development 98

DrugBank

AUGUST 20, 2024

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. The Power of Drug Repurposing Explore the immense potential of drug repurposing as a strategy for targeting undruggable targets.

Therapies 98

Therapies Pharmaceuticals Disease Research 98

Predictive Oncology

AUGUST 15, 2024

White paper validates highly reproducible drug response data. The ability to introduce patient heterogeneity in the discovery and development stages increases the Probability of Technical Success (PTS) and reduces the risk inherent in all aspects of the drug development pipeline.

Drugs 52

Drugs Drug Development 52

Predictive Oncology

AUGUST 15, 2024

White paper validates highly reproducible drug response data. The ability to introduce patient heterogeneity in the discovery and development stages increases the Probability of Technical Success (PTS) and reduces the risk inherent in all aspects of the drug development pipeline.

Drugs 52

Drugs Drug Development 52

Fierce BioTech

JULY 26, 2023

Advancements in CRISPR-Cas9 Gene Editing for Cardiovascular Disorders Download this whitepaper to dive into recent developments surrounding CRISPR-Cas9 gene editing technology, particularly concerning its use versus other gene-editing technologies. It also discussed its potential applications in vitro and in vivo drug development.

Drug Development 52

Drug Development Drugs Research 52

DrugBank

SEPTEMBER 12, 2024

At DrugBank we’re committed to improving your daily research and drug development operations. Data Exploration If you’re venturing into a new area of drug research, the Data Dictionary helps you identify relevant data fields and understand their context.

Production 98

Production Government Packaging Research 98

PPD

NOVEMBER 30, 2023

As we approach the end of 2023, it’s time to reflect on the past 12 months and how advances in drug development shaped the pharma and biotech industries. Five Predictions for the Drug Development Industry in 2024 1. Stakeholders across the drug development sphere will unlock the transformative potential of AI.

Clinical Trials 98

Clinical Trials Trials Clinical Research Drug Development 98

PPD

FEBRUARY 10, 2025

Sponsors find that an FSP solution is often the best choice to help advance their drug development projects, whether they need to fill small gaps in services or support large-scale programs with dedicated teams across functions.

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

Drug Channels

MAY 20, 2021

Karen examines trends in drug development, pricing, and healthcare. To learn more, download Six trends and tactics to thrive in the new healthcare economy , a free white paper from Wolters Kluwer. To learn more, download Six trends and tactics to thrive in the new healthcare economy , a free white paper from Wolters Kluwer.

Drug Development 52

Drug Development Drugs 52

Predictive Oncology

JUNE 28, 2023

Schedule a meeting Download case studies Optimize your formulation development challenges for biologics without disrupting your workflow. Give us 20 minutes to learn how our expertise can greatly impact your drug development efforts, especially with difficult to formulate molecules.

Clinical Trials 52

Clinical Trials Virus Drug Development Trials 52

The Pharma Data

SEPTEMBER 9, 2020

Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. Download Your Copy.

Production 52

Production Laboratories Compliance Government 52

PerkinElmer

JANUARY 7, 2020

Drug discovery is always evolving. From new processes to advanced technologies, excellence in drug discovery is the result of combining different approaches. Emerging and Resurrecting Technologies We’ve made huge strides in the drug discovery process, and it’s only getting better as we move forward.

Small Molecule 52

Small Molecule Cell Based Assays Drugs Drug Development 52

Fierce BioTech

OCTOBER 19, 2023

How cell and gene therapies are forcing sponsors to rethink safety and efficacy monitoring In this whitepaper, we look at how the industry is rising to the challenge, focusing on how cell and gene therapies are radically improving health outcomes and the technologies and techniques that are facilitating their development. Download Now.

Therapies 52

Therapies Drug Development Treatment Research 52

The Premier Consulting Blog

NOVEMBER 15, 2022

Research and development (R&D) investment decisions may be the largest risk taken by drug developers. The leadership of the company had chosen its preferred indication but, before engaging institutional investors in order to raise capital, wanted to confirm the value of the two different development programs.

Marketing 52

Marketing International Drug Development Production 52

Fierce BioTech

JULY 28, 2023

Download here! Charles River antibodies Advanced Cell Technology drug development Resource Type Whitepaper Charles river logo.png Fri, 07/28/2023 - 11:29 Content Channel Devices Clinical Data Biotech Research MedTech Landing Page Url More Info Byline Sponosred by: Charles River

Therapies 52

Therapies Drug Development Research Drugs 52

Fierce BioTech

SEPTEMBER 16, 2024

How next-generation phage display libraries are accelerating antibody developability Download now to learn how a next-generation phage library is overcoming the limitations of traditional antibody discovery platforms, enhancing the discovery of highly specific and effective antibody-based therapies.

Therapies 40

Therapies Drug Development Research Drugs 40

The ChEMBL-og

SEPTEMBER 17, 2020

During drug development, active pharmaceutical ingredients are often formulated as salts to provide the final pharmaceutical product. From the ChEMBL interface The ‘Drugs’ and ‘Mechanism’ views contain only parent molecules and so mechanisms are automatically mapped to the parent form.

Pharmaceuticals 52

Pharmaceuticals Drug Development Drugs Production 52

Drug Target Review

JUNE 13, 2023

Immerse yourself in exclusive content, including articles on cutting-edge cell line development and insightful interviews with industry experts. Download your FREE copy today. Don’t miss your chance to embrace the future of cellular therapies – dive in now! This eBook is supported by BioTechne.

Engineering 52

Engineering Pharmacy Drug Development Therapies 52

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

Alta Sciences

JANUARY 24, 2024

Discover the Power of Driving Simulations for CNS Side-Effect Analysis blussier Wed, 01/24/2024 - 18:25 HTML Start Your Driving Trial Quickly—Simulators On-Site Driving simulator studies are a safe, efficient, and effective alternative to on-the-road driving trials for CNS-active drugs. jpg Tags Clinical Trials Weight 1

Clinical Trials 40

Clinical Trials Trials FDA Drug Development 40

Conversations in Drug Development Trends

MARCH 7, 2024

When conducting first-in-human (FIH) clinical trials, small to midsize pharmaceutical and biotechnology companies are faced with several crucial choices that can shape the trajectory of their drug development pathway. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.

Clinical Trials 52

Clinical Trials Trials FDA Drug Development 52

Alta Sciences

NOVEMBER 20, 2024

Now Available Online — Scientific Posters Presented at Eurotox 2024! EXPLORE Related resources you may be interested in: eBook: Nonclinical Studies in Cell and Gene Therapy Webinar: Best Practices to Reduce Animal Use in Toxicology Studies Webpage: The Use of Miniature Swine in Preclinical Studies Image alta-blog_4_2.jpg

Therapies 40

Therapies Drug Development Research Drugs 40

Conversations in Drug Development Trends

JUNE 13, 2024

Pharmacogenomics (PGx), the study of how genes affect a person’s response to drugs, has brought significant changes to the clinical trial industry. This groundbreaking approach can help tailor medical treatments to an individual’s genetic makeup, considerably enhancing drug efficacy and safety while minimizing adverse drug reactions.

DNA 72

DNA Compliance Clinical Trials Trials 72

Alta Sciences

JULY 17, 2023

Discover the Benefits of Altasciences' Centralized Program Management mecabana Mon, 07/17/2023 - 15:59 HTML Fewer Hand-Offs for Shorter Timelines and Reduced Costs Imagine the convenience of having a single point of contact guiding you through each step of drug development, from preclinical to early phase clinical studies.

Drug Development 40

Drug Development Production Research Drugs 40

The Pharma Data

JANUARY 7, 2021

To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: CEO Laurie Heilmann will be presenting the strategic roadmap for accelerating growth of tech-enabled drug discovery in cancer. Click image above to view full announcement.

Pharmaceutical Companies 52

Pharmaceutical Companies Therapies Science Pharmaceuticals 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) has cleared Armata’s IND to initiate a clinical trial of its lead therapeutic candidate, AP-PA02, in Pseudomonas aeruginosa infections. . Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. .

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Drugs 52

Drug Channels

OCTOBER 4, 2021

Exclusive Offer – Download the agenda and register today – Be sure to use your exclusive promo code DC4RARE10 to save 10% off* of your registration. Exclusive Offer – Download the agenda and register today – Be sure to use your exclusive promo DC4RARE10 to save 10% off* of your registration. Drug Channels, or any of its employees.

Disease 40

Disease Drug Development Engineering FDA 40

The Pharma Data

DECEMBER 14, 2020

”) platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. . DALLAS , Dec. Lantern’s A.I.

Clinical Trials 52

Clinical Trials DNA Drugs Therapies 52

Conversations in Drug Development Trends

APRIL 15, 2024

As the clinical research landscape continually evolves, the choice of a Contract Research Organization (CRO) partner can significantly impact the success of drug development programs. Discover how Worldwide is positioned to meet your needs with agility, expertise, and a truly personalized approach.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Pharmaceutical Companies 52

The Pharma Data

JANUARY 13, 2021

14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. We are excited to attract such top tier talent from the psychedelic drug development community.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

PPD

MARCH 21, 2024

When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. A number of strategies can be adopted to put the needs of the child at the center of the study.

Clinical Trials 52

Clinical Trials Trials Drug Development Treatment 52

PPD

NOVEMBER 21, 2023

The drug development industry is constantly adapting and evolving to bring novel therapeutics to market to improve the lives of patients across the globe. While the drug development industry experienced setbacks during the COVID-19 pandemic, the field  is again gaining momentum reminiscent of its pre-pandemic pace.

Clinical Development 52

Clinical Development Clinical Trials Trials Clinical Research 52

PPD

OCTOBER 2, 2024

In a recent survey of drug developers about their outsourcing practices, 41% of respondents increased their use of FSP engagements compared to two years ago. Download the white paper The post Evolution of Clinical Operations Drives FSP Staffing Models to the Forefront appeared first on PPD.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Trials 52

Metabolite Tales Blog

NOVEMBER 17, 2022

Roquinimex (Linomide), a drug developed by Pfizer for the treatment of multiple sclerosis, is structurally related to laquinimod. It may be an adverse effect related to exposure to parent drug or to metabolites other than the N- dealkylated metabolites. In a 2021 publication, Rothhammer et al. The fun slides are at the end.

International 52

International Licensing Licensing Treatment 52

The Pharma Data

JANUARY 10, 2021

(Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, today announced it has submitted an Investigational New Drug (IND) application with the U.S. View original content to download multimedia: [link]. Securities and Exchange Commission. Source link.

FDA 52

FDA Clinical Trials Small Molecule Therapies 52